Metformin role in Parkinson’s disease: a double-sword effect

• Published in: Molecular and cellular biochemistry 2024-04, Vol.479 (4), p.975-991
• Main Authors: Alrouji, Mohamed, Al-kuraishy, Hayder M., Al-Gareeb, Ali I., Ashour, Nada A., Jabir, Majid S., Negm, Walaa A., Batiha, Gaber El-Saber
• Format: Article
• Language: English
• Subjects: Adenosine kinase; Adenosine monophosphate; AMP; Biochemistry; Biomedical and Life Sciences; Cancer Research; Cardiology; Degeneration; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Disease; Dopamine receptors; Folic acid; Hyperhomocysteinemia; Hypoglycemia; Insulin; Insulin resistance; Kinases; Life Sciences; Medical Biochemistry; Metformin; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Neuropathology; Neuroprotection; Oxidative stress; Parkinson's disease; Pathogenesis; Sensitizing; Substantia nigra; Synuclein; Vitamin deficiency
• ISSN: 0300-8177; 1573-4919
• DOI: 10.1007/s11010-023-04771-7

Parkinson’s disease (PD) is a common neurodegenerative disease developed due to the degeneration of dopaminergic neurons in the substantia nigra. There is no single effective treatment in the management of PD. Therefore, repurposing effective and approved drugs like metformin could be an effective strategy for managing PD. However, the mechanistic role of metformin in PD neuropathology was not fully elucidated. Metformin is an insulin-sensitizing agent used as a first-line therapy in the management of type 2 diabetes mellitus (T2DM) and has the ability to reduce insulin resistance (IR). Metformin may have a beneficial effect on PD neuropathology. The neuroprotective effect of metformin is mainly mediated by activating adenosine monophosphate protein kinase (AMPK), which reduces mitochondrial dysfunction, oxidative stress, and α-synuclein aggregation. As well, metformin mitigates brain IR a hallmark of PD and other neurodegenerative diseases. However, metformin may harm PD neuropathology by inducing hyperhomocysteinemia and deficiency of folate and B12. Therefore, this review aimed to find the potential role of metformin regarding its protective and detrimental effects on the pathogenesis of PD. The mechanistic role of metformin in PD neuropathology was not fully elucidated. Most studies regarding metformin and its effectiveness in PD neuropathology were observed in preclinical studies, which are not fully translated into clinical settings. In addition, metformin effect on PD neuropathology was previously clarified in T2DM, potentially linked to an increasing PD risk. These limitations hinder the conclusion concerning the therapeutic efficacy of metformin and its beneficial and detrimental role in PD. Therefore, as metformin does not cause hypoglycemia and is a safe drug, it should be evaluated in non-diabetic patients concerning PD risk.